Core Insights - Astria Therapeutics, Inc. granted stock options to purchase 40,000 shares of its common stock as part of its 2022 Inducement Stock Incentive Plan [1][2] - The stock options were granted to two new employees as an inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4) [2] - The exercise price of the options is set at $14.98, equal to the closing price of Astria's common stock on the grant date, March 1, 2024 [2] Company Overview - Astria Therapeutics is focused on developing therapies for allergic and immunological diseases, with a mission to provide life-changing treatments [3] - The company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein, currently in clinical development for hereditary angioedema [3] - The second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for atopic dermatitis [3]
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)